These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25695953)

  • 1. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.
    Becker MA; Haluska P; Bale LK; Oxvig C; Conover CA
    Mol Cancer Ther; 2015 Apr; 14(4):973-81. PubMed ID: 25695953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    Torres D; Hou X; Bale L; Heinzen EP; Maurer MJ; Zanfagnin V; Oberg AL; Conover C; Weroha SJ
    PLoS One; 2019; 14(11):e0224564. PubMed ID: 31751381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity.
    Mikkelsen JH; Resch ZT; Kalra B; Savjani G; Kumar A; Conover CA; Oxvig C
    Oncotarget; 2014 Feb; 5(4):1014-25. PubMed ID: 24572990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of pregnancy-associated plasma protein-A in ovarian cancer cells promotes tumor growth in vivo.
    Boldt HB; Conover CA
    Endocrinology; 2011 Apr; 152(4):1470-8. PubMed ID: 21303951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
    Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
    Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IGF-PAPP-A-Stanniocalcin Axis in Serum and Ascites Associates with Prognosis in Patients with Ovarian Cancer.
    Hjortebjerg R; Høgdall C; Hansen KH; Høgdall E; Frystyk J
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
    Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
    PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice.
    Tuppurainen L; Sallinen H; Karvonen A; Valkonen E; Laakso H; Liimatainen T; Hytönen E; Hämäläinen K; Kosma VM; Anttila M; Ylä-Herttuala S
    Int J Gynecol Cancer; 2017 Jun; 27(5):879-886. PubMed ID: 28498260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
    Zhao Y; Cao J; Melamed A; Worley M; Gockley A; Jones D; Nia HT; Zhang Y; Stylianopoulos T; Kumar AS; Mpekris F; Datta M; Sun Y; Wu L; Gao X; Yeku O; Del Carmen MG; Spriggs DR; Jain RK; Xu L
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2210-2219. PubMed ID: 30659155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
    Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
    Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
    Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
    Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.
    Tanaka Y; Kobayashi H; Suzuki M; Hirashima Y; Kanayama N; Terao T
    Int J Cancer; 2004 Apr; 109(3):336-47. PubMed ID: 14961570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes.
    Prithviraj P; Anaka M; Thompson EW; Sharma R; Walkiewicz M; Tutuka CSA; Behren A; Kannourakis G; Jayachandran A
    Sci Rep; 2020 Aug; 10(1):13779. PubMed ID: 32792532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
    Heitzeneder S; Sotillo E; Shern JF; Sindiri S; Xu P; Jones R; Pollak M; Noer PR; Lorette J; Fazli L; Alag A; Meltzer P; Lau C; Conover CA; Oxvig C; Sorensen PH; Maris JM; Khan J; Mackall CL
    J Natl Cancer Inst; 2019 Sep; 111(9):970-982. PubMed ID: 30698726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Inhibition of Pregnancy-Associated Plasma Protein-A Activity Reduces Atherosclerotic Plaque Burden in Mice.
    Conover CA; Bale LK; Oxvig C
    J Cardiovasc Transl Res; 2016 Feb; 9(1):77-9. PubMed ID: 26733326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
    Smith YE; Toomey S; Napoletano S; Kirwan G; Schadow C; Chubb AJ; Mikkelsen JH; Oxvig C; Harmey JH
    BMC Cancer; 2018 Oct; 18(1):1016. PubMed ID: 30348128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer.
    Ke FY; Chen WY; Lin MC; Hwang YC; Kuo KT; Wu HC
    Cancer Sci; 2020 Oct; 111(10):3478-3492. PubMed ID: 32648337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.